Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies – page 141

1 888 clinical trials in Ottignies, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies

Open in trial search

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer+6

Not recruiting

Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

HIV infection

Not recruiting

Study Comparing Integrase Inhibitor (Bictegravir) and Boosted Protease Inhibitor (Darunavir) Treatments for Patients with Advanced HIV Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:NEAT ID Foundation

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3018250
  • Sponsor:Bayer AG

Crohn's disease

Not recruiting

Study on Managing Moderate Postoperative Recurrence in Crohn's Disease with Infliximab for Patients After Ileocolonic Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:i-GETAID

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness of Dexmedetomidine, Ropivacaine, and Dexamethasone for Pain Relief in Patients Undergoing Shoulder Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Algemeen ziekenhuis Rivierenland

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Doxorubicin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies

What the registry says about research in the country

01 Neurology and Consciousness Disorders

Clinical research in Ottignies includes studies focused on nervous system diseases and the recovery of patients with disorders of consciousness after severe brain injury or coma. These trials are exploring whether targeted therapies can improve wakefulness, responsiveness, and overall neurological recovery.

  • Evaluation of ketamine for post-comatose patients with impaired consciousness
  • Assessment of apomorphine hydrochloride for severe brain injury and consciousness recovery
  • Study of zolpidem responses in patients with disorders of consciousness
  • Research into the mechanisms behind paradoxical neurological responses

Together, these trials aim to improve treatment options and deepen understanding of how the brain may respond to therapy in complex neurological conditions.

02 Respiratory Infections and Critical Care

Another active area of research covers respiratory tract diseases, especially severe community-acquired pneumonia and broader respiratory tract infection care in hospitalized patients. The goal is to identify better ways to support recovery and reduce serious outcomes in people admitted with acute infections.

  • Testing supportive interventions for hospitalized patients with acute respiratory tract infection
  • Evaluating treatment options for severe community-acquired pneumonia
  • Measuring effects on survival and recovery over time

This line of research is particularly relevant for intensive care settings, where timely and effective treatment can strongly influence patient outcomes.

03 Oncology and Breast Cancer

In the field of neoplasms, trials are studying advanced breast cancer with specific genetic features, including ER-positive and HER2-negative disease. Research is centered on whether new treatment combinations can improve disease control in patients with hard-to-treat cancers.

  • Testing a combination approach for selected metastatic breast cancer patients
  • Focusing on tumors with BRCA and HRR alterations
  • Assessing benefits in patients with advanced hormone-receptor-positive disease

These studies are designed to evaluate treatment effectiveness and offer more personalized options for people with genetically defined cancer subtypes.

04 Epilepsy and Rare Neurological Syndromes

Research in nervous system diseases also includes long-term treatment studies for rare epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome. The emphasis is on improving seizure control while keeping therapy safe and tolerable over time.

  • Long-term safety evaluation of soticlestat as add-on therapy
  • Support for patients already receiving standard epilepsy care
  • Focus on chronic management of Dravet syndrome and Lennox-Gastaut syndrome

This research is important for families and clinicians seeking better options for rare and severe seizure disorders.

05 Women’s Health and Viral Infections

Within female urogenital diseases and pregnancy-related conditions, clinical trials are examining human papillomavirus infection and strategies to help clear persistent genital HPV. The main purpose is to test whether new approaches can improve infection outcomes and reduce long-term risk.

  • Comparing a candidate intervention with placebo for genital HPV clearance
  • Targeting high-risk oncogenic HPV infections
  • Supporting prevention efforts in women’s health

This area links infection control with cancer prevention, making it a meaningful focus in preventive medicine.

06 Vision Research and Physiological Responses

A smaller but distinctive research stream examines physiological processes in people with acquired partial or total vision impairments and in neurotypical volunteers. These studies aim to better understand unusual responses to treatment and how such responses may inform personalized care.

  • Studying temporary visual improvement in patients with vision impairments
  • Comparing responses in volunteers and patient groups
  • Exploring how unusual drug responses may reveal biological mechanisms

The findings may help clarify why some individuals respond differently to the same treatment and support more tailored clinical decisions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.